Vallerie McLaughlin
Kim A Eagle M.D. Endowed Professor of Cardiovascular Medicine
Program Associate, Internal Medicine
Professor of Internal Medicine, Medical School
Office:
Michigan Medicine
Cardiovascular Medicine
1500 E. Medical Center Drive, SPC 5853
Ann Arbor, Michigan 48109-5853
Cardiovascular Medicine
1500 E. Medical Center Drive, SPC 5853
Ann Arbor, Michigan 48109-5853
Email:
[email protected]
Phone:
Available to mentor
Vallerie McLaughlin
Professor
Manage Your Profile
Qualifications
-
MDNorthwestern University Medical School, Evanston, IL, United States
1985 - 1989
-
BSNorthwestern University, Evanston, IL, United States
1981 - 1985
Center Memberships
-
Center MemberSamuel and Jean Frankel Cardiovascular Center
Research Overview
1. Pulmonary Hypertension
2. Pulmonary vascular disease
Recent Publications
-
Brener MI, Badano LP, Galloo X, Muraru D, Pinney SP, McLaughlin VV, Hausleiter J, Lurz P, Le Ruz R, van Mieghem NM, Weckbach LT, Ailawadi G, Praz F, Lindman BR, Salavitabar A, Chehab O, Stocker TJ, Lindenfeld J, Leon MB, Burkhoff D, Hahn RT. Journal of the American College of Cardiology, 2026 Nov 10; 88 (19): 2221 - 2243.Journal ArticleRight Heart Dysfunction in Valvular Heart Disease: Epidemiology, Prognosis, and Management Considerations
DOI:10.1016/j.jacc.2026.08.035 -
Gomberg-Maitland M, Ghofrani HA, Gibbs JSR, Hoeper MM, Humbert M, McLaughlin VV, Preston IR, Souza R, Waxman AB, Miller B, Lin J, Shi Y, Perchenet L, Strait J, Cornell AG, Badesch DB. Chest, 2026 Nov 1; 170 (5): 1593 - 1598.Journal ArticleSotatercept Safety and Efficacy in Intermediate-Low Risk Pulmonary Arterial Hypertension: A Pooled Analysis of PULSAR and STELLAR
DOI:10.1016/j.chest.2026.04.056 PMID: 42208730 -
Farber HW, Chakinala MM, Hemnes AR, Chin KM, Highland KB, McLaughlin VV, Melendres-Groves LD, Cho M, Doad G, Fatehi E, Han M, Rahman M, Strachan P, Tobore T, Kim NH. Journal of Racial and Ethnic Health Disparities, 2026 Oct 1; 13 (5): 4283 - 4295.Journal ArticleCharacteristics of Patients with Pulmonary Arterial Hypertension Receiving Selexipag in the SPHERE Registry by Race and Ethnicity
DOI:10.1007/s40615-025-02579-3 PMID: 40760219 -
McLaughlin VV, Solum D, Lachant D, Ataya A, Barberà JA, Meyer GB, Chang SA, Channick R, Church C, Feenstra J, Gaine S, Giannakoulas G, Jerjes-Sanchez C, Khanna D, Kim NH, Oudiz R, Preston IR, Sood N, Torres F, Vachiery JL, Pulido T, Cella D, Deng C, Escudero M, Lacasse V, Peterson L, Benza R, Humbert M. Lancet, 2026 Aug 8; 408 (10554): 521 - 531.Journal ArticleRalinepag for the treatment of pulmonary arterial hypertension (ADVANCE OUTCOMES): a randomised, double-blind, placebo-controlled phase 3 study
DOI:10.1016/S0140-6736(26)01011-1 PMID: 42520828 -
Osterhout R, Boucly A, Benza RL, Channick RN, Chin KM, Frantz RP, Hemnes AR, Howard LS, McLaughlin VV, Sitbon O, Vachiéry JL, Zamanian RT, Aranda R, Cravets M, Ding Z, Duong-Verlé T, Mottola D, Roscigno RF, Sitapara R, Zisman LS, Bruey JM, Ghofrani HA. American Journal of Respiratory and Critical Care Medicine, 2026 Aug 1; 212 (8): 1832 - 1837.Journal ArticleCirculating biomarker results from a phase 2 study of seralutinib in pulmonary arterial hypertension
DOI:10.1093/ajrccm/aamag175 PMID: 42104009 -
Moles VM, Cascino T, McLaughlin VV. American Journal of Respiratory and Critical Care Medicine, 2026 Aug 1; 212 (8): 1826 - 1828.Journal ArticleSotatercept and prostacyclin de-escalation in stable pulmonary arterial hypertension: a single-center case series
DOI:10.1093/ajrccm/aamag147 PMID: 42085278 -
Cascino TM, Fudim M, McLaughlin VV. Journal of the American College of Cardiology, 2026 Jul 28; 88 (4): 433 - 436.Journal ArticleFrom Clinical Success to Physiologic Understanding
DOI:10.1016/j.jacc.2026.03.049 PMID: 42017885 -
Reddy R, Moutchia J, Ravichandran A, Runo J, Badesch DB, Moss J, Burger C, De Marco T, Horn E, Ataya A, Bryant A, Al-Naamani N, Kawut SM, Willson M, Raina A, Raval A, Muralidhar A, Roberts E, Dong LW, Bakshi S, Ivy DD, Critser P, Hirsch R, Heresi G, Krishnan U, Krishnan S, Sager J, Bensimhon H, Fortin T, Swisher J, Presberg K, Gomberg-Maitland M, Kelly B, Awdish R, Safdar Z, Prohaska C, Shlobin O, Kingrey J, Cirulis M, Mathai S, Moretta D, Wells R, Frantz R, Scott R, Rahul Argula M, Matuschak G, George MP, Boyce P, McConnell JW, Desai S, Kaplan A, Ventetuolo C, Klinger J, Montgomery G, Yung D, Eggert M, Zamanian R, Varghese N, Farr G, Avdalovic M, Saggar R, Channick R, Fineman J, Elwing J, Bull T, Foley R, Cadaret L, Williamson T, Ramani G, McLaughlin V, Thenappan T, Wichman T, Melendres-Groves L, Ford HJ, Chan S, White RJ, Clapham K, Badlam J, Mihalek A, Leary P, Bartolome S, Austin E, Hemnes A, Grinnan D, Chakinala M, Singh I. Pulmonary Circulation, 2026 Jul 1; 16 (3):Journal ArticlePulmonary Arterial Hypertension in Octogenarians: The Pulmonary Hypertension Association Registry
DOI:10.1002/pul2.70387
Featured News & Stories
Health Lab
Biologic drug reduces symptoms, hospitalization for severe pulmonary hypertension after diagnosis
Prescribing the biologic drug sotatercept alongside standard treatment for the most severe form of pulmonary hypertension significantly reduces the likelihood of worsening disease when added within the first year after diagnosis, according to a study published in the New England Journal of Medicine by Michigan Medicine.